Search Results

There are 4252 results for: content related to: Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study

  1. Dopamine agonists for the treatment of restless legs syndrome

    Intervention Review

    The Cochrane Library

    Hanna Scholz, Claudia Trenkwalder, Ralf Kohnen, Levente Kriston, Dieter Riemann and Magdolna Hornyak

    Published Online : 15 MAR 2011, DOI: 10.1002/14651858.CD006009.pub2

  2. You have free access to this content
    High-sensitivity quantitation of cabergoline and pergolide using a triple-quadrupole mass spectrometer with enhanced mass-resolution capabilities

    Journal of Mass Spectrometry

    Volume 38, Issue 7, July 2003, Pages: 743–751, Nicola Hughes, Witold Winnik, Jean-Jacques Dunyach, Ma'an Amad, Maurizio Splendore and Gary Paul

    Version of Record online : 15 JUL 2003, DOI: 10.1002/jms.489

  3. You have free access to this content
    Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice

    Movement Disorders

    Volume 23, Issue 16, 15 December 2008, Pages: 2267–2302, Claudia Trenkwalder, Wayne A. Hening, Pasquale Montagna, Wolfgang H. Oertel, Richard P. Allen, Arthur S. Walters, Joao Costa, Karin Stiasny-Kolster and Cristina Sampaio

    Version of Record online : 16 OCT 2008, DOI: 10.1002/mds.22254

  4. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

    Movement Disorders

    Volume 26, Issue S3, October 2011, Pages: S2–S41, Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz and Cristina Sampaio

    Version of Record online : 21 OCT 2011, DOI: 10.1002/mds.23829

  5. You have free access to this content
    Regression of Cardiac Valvulopathy Related to Ergot-Derived Dopamine Agonists

    Cardiovascular Therapeutics

    Volume 29, Issue 6, December 2011, Pages: 404–410, Renzo Zanettini, Angelo Antonini, Gemma Gatto, Rosa Gentile, Silvana Tesei and Gianni Pezzoli

    Version of Record online : 11 JUN 2010, DOI: 10.1111/j.1755-5922.2010.00169.x

  6. Parkinson's Disease

    Standard Article

    Wiley Handbook of Current and Emerging Drug Therapies

    Published Online : 13 OCT 2006, DOI: 10.1002/9780470041000.cedt084

  7. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

    Movement Disorders

    Volume 21, Issue 3, March 2006, Pages: 343–353, Wolfgang H. Oertel, Erik Wolters, Cristina Sampaio, Santiago Gimenez-Roldan, Bruno Bergamasco, Max Dujardin, Donald G. Grosset, Guy Arnold, Klaus L. Leenders, Hans-Peter Hundemer, Alberto Lledó, Andrew Wood, Paul Frewer and Johannes Schwarz

    Version of Record online : 6 OCT 2005, DOI: 10.1002/mds.20724

  8. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists

    Movement Disorders

    Volume 22, Issue 13, 15 October 2007, Pages: 1936–1942, Gregor Simonis, Joerg T. Fuhrmann and Ruth H. Strasser

    Version of Record online : 20 JUL 2007, DOI: 10.1002/mds.21639

  9. The frequency of cardiac valvular regurgitation in Parkinson's disease

    Movement Disorders

    Volume 23, Issue 7, 15 May 2008, Pages: 935–941, Kazuo Yamashiro, Miki Komine-Kobayashi, Taku Hatano, Takao Urabe, Hideki Mochizuki, Nobutaka Hattori, Yoshitaka Iwama, Hiroyuki Daida, Michi Sakai, Takeo Nakayama and Yoshikuni Mizuno

    Version of Record online : 8 APR 2008, DOI: 10.1002/mds.22036

  10. Levodopa for the treatment of restless legs syndrome

    Intervention Review

    The Cochrane Library

    Hanna Scholz, Claudia Trenkwalder, Ralf Kohnen, Levente Kriston, Dieter Riemann and Magdolna Hornyak

    Published Online : 15 FEB 2011, DOI: 10.1002/14651858.CD005504.pub2

  11. The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

    Movement Disorders

    Volume 26, Issue 5, April 2011, Pages: 801–806, Vibeke Guldbrand Rasmussen, Karen Østergaard, Erik Dupont and Steen Hvitfeldt Poulsen

    Version of Record online : 24 JAN 2011, DOI: 10.1002/mds.23470

  12. You have free access to this content
    Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease

    European Journal of Neurology

    Volume 20, Issue 1, January 2013, Pages: 5–15, J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli and W. H. Oertel

    Version of Record online : 22 DEC 2012, DOI: 10.1111/j.1468-1331.2012.03866.x

  13. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia

    International Journal of Clinical Practice

    Volume 62, Issue 12, December 2008, Pages: 1864–1869, F. Bogazzi, S. Buralli, L. Manetti, V. Raffaelli, T. Cigni, M. Lombardi, F. Boresi, S. Taddei, A. Salvetti and E. Martino

    Version of Record online : 6 MAY 2008, DOI: 10.1111/j.1742-1241.2008.01779.x

  14. Cabergoline for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Carl E Clarke and Katherine HO Deane

    Published Online : 22 JAN 2001, DOI: 10.1002/14651858.CD001518

  15. Dopamine agonists in the treatment of prolactinoma: are they still first choice?

    Internal Medicine Journal

    Volume 41, Issue 2, February 2011, Pages: 156–161, C. M. Ogilvie and S. R. Milsom

    Version of Record online : 25 FEB 2011, DOI: 10.1111/j.1445-5994.2010.02410.x

  16. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists

    Movement Disorders

    Volume 24, Issue 1, 15 January 2009, Pages: 129–133, Frank Andersohn and Edeltraut Garbe

    Version of Record online : 17 NOV 2008, DOI: 10.1002/mds.22385

  17. Efficacy and safety of high-dose cabergoline in Parkinson's disease

    Acta Neurologica Scandinavica

    Volume 113, Issue 1, January 2006, Pages: 18–24, P. Odin, C. Oehlwein, A. Storch, U. Polzer, G. Werner, R. Renner, M. Shing, A. Ludolph and P. Schüler

    Version of Record online : 6 DEC 2005, DOI: 10.1111/j.1600-0404.2005.00514.x

  18. ORIGINAL ARTICLE: Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia

    Clinical Endocrinology

    Volume 73, Issue 3, September 2010, Pages: 369–374, Tricia Tan, Ines Z. Cabrita, Davina Hensman, Joanna Grogono, Waljit S. Dhillo, Kevin C. Baynes, Joseph Eliahoo, Karim Meeran, Stephen Robinson, Petros Nihoyannopoulos and Niamh M. Martin

    Version of Record online : 17 AUG 2010, DOI: 10.1111/j.1365-2265.2010.03827.x

  19. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications

    Intervention Review

    The Cochrane Library

    Rebecca Stowe, Natalie Ives, Carl E Clarke, Katherine Deane, van Hilten, Keith Wheatley, Richard Gray, Kelly Handley and Alex Furmston

    Published Online : 7 JUL 2010, DOI: 10.1002/14651858.CD007166.pub2

  20. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Carl E Clarke and Katherine HO Deane

    Published Online : 22 JAN 2001, DOI: 10.1002/14651858.CD001519